touchNEUROLOGY caught up with Tahseen Mozaffar (University California, Irvine, CA, USA) to discuss the results from the PROPEL study (NCT03729362) investigating the use of AT-GAA for the treatment of late-onset Pompe disease.
- Could you tell us a little about late onset Pompe disease and the unmet needs in its treatment? (0:15)
- What is AT-GAA and what is its mechanism of action? (1:28)
- What clinical evidence to date supports the use of AT-GAA for the treatment of late-onset Pompe disease? (3:29)
- What are the aims and design of the PROPEL study? (7:51)
- What are the clinical endpoints of the study? (8:44)
Disclosures: Tahseen Mozaffar has served as an advisor to Amicus on trial design; and has served as an investigator on Amicus’ clinical trials on Pompe Disease.
Support: Interview and filming supported by Touch Medical Media
Share this Video
Related Videos In Neuromuscular Diseases
Anthony Béhin, EAN 2023: Highlights in myasthenia gravis
Dr Anthony Béhin (University Hospitals Pitié Salpêtrière, Paris, France) discusses highlights from the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of myasthenia gravis. Disclosures: Anthony Béhin is a consultant for Alexion, Argenx, UCB, Sanofi and Ultragenyx pharmaceutical. He has received grant/research support from the Association Institut de Myologie and is on the […]
Luca Leonardi, EAN 2023: Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis
Dr Luca Leonardi (Sapienza University of Rome, Italy) summarizes the take-home messages from his study assessing skin biopsy as a marker of disease onset and severity in hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a treatable disease. The abstract ‘EJoN: Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary […]
Sabrina Sacconi, EAN 2023: The MycarinG study – rozanolixizumab in the treatment of muscle-specific kinase autoantibody-positive myasthenia gravis
Muscle-specific kinase autoantibody-positive (MuSK-Ab+) generalised myasthenia gravis (gMG) is usually more clinically severe than acetylcholine receptor autoantibody-positive (AChR-Ab+) gMG. The Phase 3 MycarinG study analysed rozanolixizumab in patients with AChR-Ab+ or MuSKAb+ gMG. Dr Sabrina Sacconi (Côte d’Azur University, Nice, France) summarizes the take-home messages from her presentation of the results of the study. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!